Biotherapeutics News and Research

RSS

GENova Biotherapeutics files patent to combat breast cancer

(OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has filed a patent for a potential blockbuster drug target that combats breast cancer.

10 Sep 2009

GENova Biotherapeutics discusses its anti-cancer drug development strategy

GENova Biotherapeutics, Inc., ("GENova"), today released important information about its anti-cancer drug development strategy and its unique niche in the drug development industry.

9 Sep 2009

aTyr Pharma expands intellectual property portfolio, receives its fifteenth patent

aTyr Pharma announced today that the US Patent office has issued patent US 7,572,452 B2, titled "Method for Stimulating Wound Healing." aTyr Pharma is the sole assignee of this patent, and Professor Sunghoon Kim, a scientific co-founder of aTyr Pharma, is the inventor.

9 Sep 2009

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

9 Sep 2009

Protalix receives orphan drug designation for prGCD

Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA’s Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company’s proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.

8 Sep 2009

Intrexon purchases assets and operations of Avalon Pharmaceutical

Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the purchase of assets and operations of Avalon Pharmaceutical, Inc., a wholly-owned subsidiary of Clinical Data, Inc.

1 Sep 2009

Cancer Immunotherapy Index of ten cancer immunotherapy stocks increases by 23%

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009. The CI Index was developed by Mentor Capital as a peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector.

29 Aug 2009

Oxygen Biotherapeutics to present at the Rodman & Renshaw Annual Global Investment Conference

Oxygen Biotherapeutics, Inc. today announced that the company will present at investor conferences in New York on Sept. 9 and Zurich on Sept. 10, 2009.

26 Aug 2009

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

GENova Biotherapeutics, Inc., ("GENova") - (OTCBB: GVBP.OB), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Aaron Whiteman as its Chief Executive Officer.

19 Aug 2009

Trial tests potential new angina treatment

As part of a multi-center clinical trial, UC San Diego Medical Center is evaluating the safety and effectiveness of a potential new way to treat angina - by injecting a protein that stimulates the growth of new oxygen-rich blood vessels directly into the heart. Angina is a debilitating form of chest pain caused by coronary artery disease that affects more than nine million Americans.

20 May 2009

Oxford BioTherapeutics and GSK form alliance to develop cancer therapeutic antibodies

Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.

18 May 2009

Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009

Good bacteria may provide effective vehicle for an oral vaccine against anthrax

Researchers at North Carolina State University have discovered that the good bacteria found in dairy products and linked to positive health benefits in the human body might also be an effective vehicle for an oral vaccine that can provide immunity to anthrax exposure.

17 Feb 2009

FDA approves orphan drug ATryn anticoagulant

The U.S. Food and Drug Administration has issued its first approval for a biological product produced by genetically engineered (GE) animals.

8 Feb 2009

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein.

8 Dec 2008

CardioVascular BioTherapeutics doses first patient in trial for severe coronary heart disease

CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.

25 Nov 2008

FDA accepts ATryn biologics license application

The US Food and Drug Administration, or FDA, has accepted for review GTC Biotherapeutics, Inc.'s Biologics License Application, or BLA, for ATryn.

6 Oct 2008

FDA grants approval to Talecris Biotherapeutics for Gamunex for neurological disorder CIDP

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills.

15 Sep 2008

FDA approves Gamunex for chronic inflammatory demyelinating polyneuropathy

The U.S. Food and Drug Administration has announced that it has approved an immune globulin product called Gamunex for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.

14 Sep 2008

FDA assigns priority review to ATryn from GTC Biotherapeutics

The US Food and Drug Administration, or FDA, has assigned Priority Review to GTC Biotherapeutics, Inc.'s Biologic License Application, or BLA, for ATryn.

4 Sep 2008